Advances in T-cell Immunotherapies

Stroncek, David F.; Reddy, Opal L.; Highfill, Steven L.; Panch, Sandhya R.

doi:10.1016/j.hoc.2019.05.006

Cited by 5 publications

(10 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T cell immunotherapies ( 34 , 35 ) have revolutionized medicine and even called by The New York Times: “The medical equivalent of splitting the atom” ( 28 ).…”

Section: T Cell Immunotherapies—“the Medical Equivalent Of Splitting mentioning

confidence: 99%

“…Current adoptive/cellular T cell therapies include mainly the following types: donor lymphocyte infusions, tumor-infiltrating lymphocytes, T-cell receptor-engineered T cells, chimeric antigen receptor (CAR) T cells, and virus-specific T cells. These T cell immunotherapies are reviewed in many papers, among them ( 34 , 35 ).…”

Section: T Cell Immunotherapies—“the Medical Equivalent Of Splitting mentioning

confidence: 99%

See 1 more Smart Citation

T Cells Plead for Rejuvenation and Amplification; With the Brain’s Neurotransmitters and Neuropeptides We Can Make It Happen

Levite

2021

Front. Immunol.

View full text Add to dashboard Cite

T cells are essential for eradicating microorganisms and cancer and for tissue repair, have a pro-cognitive role in the brain, and limit Central Nervous System (CNS) inflammation and damage upon injury and infection. However, in aging, chronic infections, acute SARS-CoV-2 infection, cancer, chronic stress, depression and major injury/trauma, T cells are often scarce, exhausted, senescent, impaired/biased and dysfunctional. People with impaired/dysfunctional T cells are at high risk of infections, cancer, other diseases, and eventually mortality, and become multi-level burden on other people, organizations and societies. It is suggested that “Nerve-Driven Immunity” and “Personalized Adoptive Neuro-Immunotherapy” may overcome this problem. Natural Neurotransmitters and Neuropeptides: Glutamate, Dopamine, GnRH-II, CGRP, Neuropeptide Y, Somatostatin and others, bind their well-characterized receptors expressed on the cell surface of naïve/resting T cells and induce multiple direct, beneficial, and therapeutically relevant effects. These Neurotransmitters and Neuropeptides can induce/increase: gene expression, cytokine secretion, integrin-mediated adhesion, chemotactic migration, extravasation, proliferation, and killing of cancer. Moreover, we recently found that some of these Neurotransmitters and Neuropeptides also induce rapid and profound decrease of PD-1 in human T cells. By inducing these beneficial effects in naïve/resting T cells at different times after binding their receptors (i.e. NOT by single effect/mechanism/pathway), these Neurotransmitters and Neuropeptides by themselves can activate, rejuvenate, and improve T cells. “Personalized Adaptive Neuro-Immunotherapy” is a novel method for rejuvenating and improving T cells safely and potently by Neurotransmitters and Neuropeptides, consisting of personalized diagnostic and therapeutic protocols. The patient’s scarce and/or dysfunctional T cells are activated ex vivo once by pre-selected Neurotransmitters and/or Neuropeptides, tested, and re-inoculated to the patient’s body. Neuro-Immunotherapy can be actionable and repeated whenever needed, and allows other treatments. This adoptive Neuro-Immunotherapy calls for testing its safety and efficacy in clinical trials.

show abstract

“…T cell immunotherapies ( 34 , 35 ) have revolutionized medicine and even called by The New York Times: “The medical equivalent of splitting the atom” ( 28 ).…”

Section: T Cell Immunotherapies—“the Medical Equivalent Of Splitting mentioning

confidence: 99%

Section: T Cell Immunotherapies—“the Medical Equivalent Of Splitting mentioning

confidence: 99%

T Cells Plead for Rejuvenation and Amplification; With the Brain’s Neurotransmitters and Neuropeptides We Can Make It Happen

Levite

2021

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Adoptive T cell immunotherapy has evolved as a potent tool in numerous targeted therapies against tumors, autoimmune diseases, and other dysfunctions over the last 30 years. Donor lymphocyte infusions (DLIs) and virus-specific T cells are established allogeneic T cell therapies ( Toprak 2018 ; Stroncek et al, 2019 ; Rath and Arber 2020 ; Waldman et al, 2020 ). Chimeric antigen receptor (CAR) T cell therapy is an advanced T cell therapy developed in the last decade and has strongly increased the clinical application of T cells ( Ochi et al, 2010 ; Stroncek et al, 2019 ; Rath and Arber 2020 ; Waldman et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

“…Donor lymphocyte infusions (DLIs) and virus-specific T cells are established allogeneic T cell therapies ( Toprak 2018 ; Stroncek et al, 2019 ; Rath and Arber 2020 ; Waldman et al, 2020 ). Chimeric antigen receptor (CAR) T cell therapy is an advanced T cell therapy developed in the last decade and has strongly increased the clinical application of T cells ( Ochi et al, 2010 ; Stroncek et al, 2019 ; Rath and Arber 2020 ; Waldman et al, 2020 ). In CAR T cell therapy, the T cells are genetically modified by transduction of a CAR transgene.…”

Section: Introductionmentioning

confidence: 99%

“…The antigen-specific CAR construct is expressed on the surface of the T cells, which can directly identify the target antigens, for example on tumor cells. Currently, clinically established CAR T cell therapies involve mostly autologous T cells; however, there are ongoing developments toward “off the shelf” allogenic CAR T cell therapy ( Feins et al, 2019 ; Stroncek et al, 2019 ; Depil et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions

Sudarsanam

Buhmann

Henschler

2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Ex vivo expansion of T lymphocytes is a central process in the generation of cellular therapies targeted at tumors and other disease-relevant structures, which currently cannot be reached by established pharmaceuticals. The influence of culture conditions on T cell functions is, however, incompletely understood. In clinical applications of ex vivo expanded T cells, so far, a relatively classical standard cell culture methodology has been established. The expanded cells have been characterized in both preclinical models and clinical studies mainly using a therapeutic endpoint, for example antitumor response and cytotoxic function against cellular targets, whereas the influence of manipulations of T cells ex vivo including transduction and culture expansion has been studied to a much lesser detail, or in many contexts remains unknown. This includes the circulation behavior of expanded T cells after intravenous application, their intracellular metabolism and signal transduction, and their cytoskeletal (re)organization or their adhesion, migration, and subsequent intra-tissue differentiation. This review aims to provide an overview of established T cell expansion methodologies and address unanswered questions relating in vivo interaction of ex vivo expanded T cells for cellular therapy.

show abstract

Establishment of a cell processing laboratory to support hematopoietic stem cell transplantation and chimeric antigen receptor (CAR)-T cell therapy

Mukherjee

Reddy

Panch

et al. 2021

Transfusion and Apheresis Science

View full text Add to dashboard Cite

Advances in T-cell Immunotherapies

Cited by 5 publications

References 54 publications

T Cells Plead for Rejuvenation and Amplification; With the Brain’s Neurotransmitters and Neuropeptides We Can Make It Happen

T Cells Plead for Rejuvenation and Amplification; With the Brain’s Neurotransmitters and Neuropeptides We Can Make It Happen

Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions

Establishment of a cell processing laboratory to support hematopoietic stem cell transplantation and chimeric antigen receptor (CAR)-T cell therapy

Contact Info

Product

Resources

About